Researchers developed a cohort study of more than 14,000 participants to determine whether there is an association between statin initiation and a reduced risk of mortality and major adverse cardiovascular...
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
Researchers set out to determine whether renal function could be used as both a predictor of relapse risk for patients with their first onset of aquaporin-4 (AQP4)-immunoglobulin G (IgG)-seropositive...
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
Did you watch our Multidisciplinary Roundtable on managing nutrition in patients with chronic kidney disease? Here are some highlights that you may have missed.
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
The FDA approves the first-of-its-kind treatment for anemia caused by CKD for adults who receive dialysis following the results of a randomized clinical trial.
The Work Group from the Kidney Disease: Improving Global Outcomes organization updated its set of guidelines that offers clinical practice guidelines in the treatment of chronic kidney disease and...
